Your doctor prescribed Ubrelvy because it's the right acute treatment for your migraines — and in many cases, because triptans aren't safe or effective for you. Your insurer disagreed. But a denial letter isn't the final word, and you have more power to challenge it than you probably realize.

Ubrelvy (ubrogepant) was the first oral calcitonin gene-related peptide (CGRP) medication FDA-approved specifically for treating migraine attacks. It works through an entirely different mechanism than triptans — blocking the CGRP protein involved in migraine pain, nausea, and sensitivity to light and sound, rather than constricting blood vessels. That distinction matters clinically, and it matters enormously when it comes to insurance coverage, because the very reason your doctor chose Ubrelvy is often the reason your insurer tries to deny it.

Here's what AbbVie's own access data shows: 56% of commercially insured patients are unrestricted or need only minimal prior therapy to access Ubrelvy. That means nearly half face significant coverage hurdles — prior authorization requirements, step therapy demands, or outright denials. If you're reading this, you're likely in that group.

The good news: denials can be overturned. Fewer than 1% of denied claims are ever appealed, and insurance companies bank on that silence. But when patients appeal with the right evidence and strategy, the results are dramatically different. At Claimable, over 80% of our appeals succeed in established conditions.

This guide breaks down exactly why Ubrelvy gets denied, how to identify your specific situation, and what a winning appeal looks like — including the clinical arguments, legal protections, and documentation strategies that actually move the needle.

Why Insurance Companies Deny Ubrelvy

The single most important thing to do before anything else: understand the specific reason your insurer denied coverage. The denial reason shapes your entire appeal strategy. Getting it wrong means building a case that doesn't address the actual barrier.

The Triptan Paradox: Why Ubrelvy Denials Are Often Medically Absurd

Here's the central irony of most Ubrelvy denials: your doctor likely prescribed Ubrelvy because triptans don't work for you, cause intolerable side effects, or are medically unsafe given your health history. And your insurer's most likely response is to demand that you try more triptans first.

This isn't a minor bureaucratic inconvenience. Research published in the Journal of Primary Care & Community Health found that more than 20% of commercially insured migraine patients have a cardiovascular condition that specifically contraindicates triptan use — conditions like coronary artery disease, peripheral vascular disease, uncontrolled hypertension, or history of stroke. An additional 25% have multiple cardiovascular risk factors that carry formal warnings and precautions against triptan use. That's nearly half of all migraine patients for whom triptans are either unsafe or require serious caution.

Triptans work by constricting blood vessels. That vasoconstriction is the source of both their efficacy and their risk. Ubrelvy doesn't constrict blood vessels at all — it targets the CGRP receptor, addressing migraine pain through an entirely different pathway. For patients with cardiovascular concerns, this isn't a preference. It's a medical necessity.

When an insurer requires you to try and fail triptans before approving Ubrelvy, and your medical history includes cardiovascular contraindications, they're effectively asking you to take medications your own doctor has determined could put your health at risk. That's a powerful foundation for an appeal.

Even for patients without cardiovascular issues, there are legitimate clinical reasons triptans may not be appropriate: intolerable side effects (chest tightness, tingling, fatigue), medication interactions, or simply inadequate relief. Roughly one-third of migraine patients don't respond well to triptans or can't tolerate them. Ubrelvy was developed precisely for this population.

The Most Common Ubrelvy Denial Types

Every denial letter uses insurer language designed to sound definitive. Understanding what each denial type actually means — and where the insurer's reasoning is weakest — is how you build a targeted appeal.

Step Therapy Required

This is the most frequent reason Ubrelvy is denied. Major insurers including Anthem Blue Cross, Aetna, Blue Shield, and UnitedHealthcare all typically require prior authorization for Ubrelvy, and most mandate documented failure of at least two triptans before they'll approve a gepant for acute migraine treatment. Some plans require even more — failure of triptans plus NSAIDs, or failure of specific named triptans (sumatriptan, rizatriptan) rather than the class broadly. Specific step therapy requirements vary by plan and even by state, so check your denial letter for the exact criteria your insurer applied.

The critical detail most patients miss: "failure" has a broad medical definition that works in your favor. You don't have to prove a triptan was completely ineffective. Side effects count. Contraindications count. Medical reasons a drug is inappropriate for you — cardiovascular disease, medication interactions, hemiplegic migraine — all qualify as failure. If your doctor determined triptans aren't safe for you, that is a documented failure, even if you never took a single dose.

The American Headache Society's 2021 consensus statement specifically recommends gepants like Ubrelvy for patients who have failed, cannot tolerate, or have contraindications to triptans. And the AHS's 2024 position statement goes further, establishing CGRP-targeting therapies as a first-line option for migraine treatment without requiring prior failure of older drug classes. When your insurer demands triptan trials that your doctor has already ruled out, they're contradicting the leading medical society in headache medicine.

Not Medically Necessary

This denial usually means the paperwork was too thin — not that someone carefully reviewed your history and concluded Ubrelvy isn't appropriate. The most common gaps: not specifying migraine frequency and severity, not listing prior treatments tried and why they failed, not documenting impact on daily functioning, or not explaining why Ubrelvy specifically is the right choice over other acute options.

For Ubrelvy, your prescriber's documentation should make clear why a non-vasoconstrictive acute treatment is needed. If you have cardiovascular risk factors, those need to be spelled out explicitly. If you tried triptans and experienced side effects, those side effects need to be named and described, not just referenced in passing.

Quantity Limit Exceeded

Insurer quantity limits for Ubrelvy vary more than you might expect. Some plans cap coverage at 8 tablets per month, others at 10, and some allow up to 16 (which is what AbbVie packages as a standard prescription). Ubrelvy's prescribing information notes that treating more than 8 migraines in a 30-day period hasn't been studied for safety — but that's 8 migraines, not 8 tablets. Since patients can take a second dose 2 hours after the first if needed, someone treating 4–5 migraines per month with an optional second dose may legitimately need more than 8 tablets.

If your insurer denied based on quantity, your prescriber should submit documentation confirming the clinical rationale for the prescribed amount — including migraine frequency, whether a second dose is typically needed, and why the quantity is medically appropriate.

Not on Formulary / Non-Preferred Brand

Some plans position Nurtec as their preferred CGRP medication over Ubrelvy, since Nurtec carries both acute and preventive indications. Others prefer neither and want you on triptans entirely. If your plan prefers a different medication, the appeal needs to explain why Ubrelvy specifically is the right choice for your situation.

Strong arguments for a formulary exception include: you've already tried and failed the preferred alternative, the preferred drug is contraindicated for you, or there are specific clinical reasons Ubrelvy is more appropriate. If your prescriber chose Ubrelvy because you need acute-only treatment and the other options haven't worked or aren't suitable, that rationale needs to be documented clearly.

Dose-Level Denial (50mg vs. 100mg)

Some insurers will approve Ubrelvy at the 50mg dose but deny the 100mg. Both doses showed similar rates of pain freedom in the ACHIEVE trials — 21% at 2 hours for both 50mg and 100mg — but the 100mg dose was the one studied in the landmark PRODROME trial and is often the dose prescribed for patients with more severe or harder-to-treat migraines. Dose modifications are also required for patients on certain medications, which can affect which strength is clinically appropriate.

If your insurer denied the 100mg dose, your prescriber should provide a clinical rationale: why the higher dose is needed, whether the 50mg was tried and found insufficient, or whether dose adjustments related to other medications require the 100mg formulation.

Duplicate CGRP Therapy Denial

If you're already taking an injectable CGRP medication for prevention — Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), or Vyepti (eptinezumab) — some insurers will deny Ubrelvy on the grounds that you can't use two CGRP-targeting drugs at the same time.

This denial is frequently wrong. Ubrelvy (an oral CGRP receptor antagonist for acute use) and injectable CGRP monoclonal antibodies (for prevention) work through different mechanisms and serve different clinical purposes. Published research in Advances in Therapy (Blumenfeld et al., 2022) specifically evaluated the safety and efficacy of ubrogepant in patients taking concomitant preventive CGRP monoclonal antibodies — and found no negative impact on either safety or efficacy. The Ubrelvy prescribing information itself notes that patients in clinical trials were able to use concomitant preventive medications.

A detailed clinical rationale from your neurologist or headache specialist explaining the different mechanisms, distinct indications, and published evidence supporting combination use is typically what's needed to overturn this type of denial.

Incorrect Diagnosis Code

Like all migraine medications, Ubrelvy coverage can hinge on whether the right ICD-10 code was submitted. Using a general headache code (like R51.9 for "headache, unspecified") instead of a specific migraine code will often trigger an automatic denial. The most common migraine diagnosis codes that support Ubrelvy coverage include: migraine without aura (G43.00, G43.01), migraine with aura (G43.10, G43.11), migraine unspecified (G43.90, G43.91), and chronic migraine (G43.709, G43.711).

If your denial seems to stem from a coding issue, this is usually the easiest fix — work with your prescriber's office to verify the correct code was submitted and resubmit if needed.

How to Appeal a Ubrelvy Denial: Step by Step

The insurance industry has conditioned patients to treat a denial as a final answer. It's not. Appeals are a legal right, and they work far more often than most people expect.

Step 1: Read Your Denial Letter Carefully

Every denial letter is legally required to include three things: the specific reason for denial, your appeal rights, and the deadline to file. Find the deadline first — it's the most time-sensitive detail. Most commercial plans give 180 days, but timelines vary by insurer. UnitedHealthcare allows just 65 days for most plan types. Medicare Advantage plans follow CMS guidelines of 60 days. Missing the deadline eliminates your right to appeal, so move quickly.

Step 2: Know That You Can File Your Own Appeal

Patient-initiated appeals are separate from (and in addition to) anything your doctor's office files. This is a distinction most people don't know about, and it matters. Patient appeals carry their own legal protections — mandated response timelines, the right to escalate to independent external review, and multiple levels of appeal. If your doctor's prior authorization was denied, that doesn't close the door for you. You have your own path.

Step 3: Confirm the Clinical Details With Your Prescriber

Before building your appeal, verify with your doctor's office: Was the correct migraine diagnosis code submitted? Were prior triptan trials (or contraindications to triptans) documented? Was the prescribed dose and quantity clearly justified? If the denial stems from a paperwork gap rather than a genuine coverage dispute, a corrected prior authorization resubmission may resolve the issue without a formal appeal.

Step 4: Get a Letter of Medical Necessity

A letter of medical necessity from your prescribing physician is the most important document in your appeal package. For Ubrelvy specifically, this letter should include your migraine diagnosis and frequency, a detailed history of prior treatments tried and outcomes (especially triptans — why they failed, caused side effects, or are contraindicated), any cardiovascular conditions or risk factors that make triptans unsafe, the specific clinical rationale for why Ubrelvy is the appropriate treatment, and the prescribed dose and quantity with medical justification.

How to ask: Be direct with your doctor. "My insurance denied Ubrelvy. Would you write a letter of medical necessity for my appeal? I can bring information on what the insurer typically requires." If your doctor's office isn't experienced with these, offering to share a template or outline can make a significant difference.

Step 5: Build Your Appeal Package

A complete appeal submission should include a cover letter summarizing your case, the letter of medical necessity from your prescriber, supporting clinical documentation (office visit notes showing migraine frequency, treatment history, cardiovascular history if relevant), and a personal statement explaining how the denial affects your health and daily life.

The three pillars of a winning appeal:

Your story — How migraines impact your daily life, your work, your relationships. How the denial has affected your ability to manage your condition. This isn't filler — it provides the human context that clinical data alone can't convey.

Clinical evidence — The ACHIEVE trial results, the AHS consensus statements, specific evidence supporting Ubrelvy for your situation. If cardiovascular contraindications to triptans are part of your case, the published research on triptan contraindication prevalence strengthens the argument that Ubrelvy isn't a luxury — it's a necessity.

Policy and legal analysis — How your situation meets coverage criteria under your specific plan, applicable state laws, and federal regulations like the ACA's protections for appeals and external review.

Step 6: Submit and Track

Follow the submission instructions in your denial letter exactly. Your insurer is required to respond within 30 days for standard appeals or 72 hours for urgent/expedited cases. Document everything: when you submitted, how (fax, mail, portal), and any confirmation numbers or reference IDs.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party who doesn't work for the insurer. External reviewers evaluate whether the denial was medically justified, not whether the insurer wants to pay. These reviews frequently overturn denials that make it to this stage, because the standard of review shifts from the insurer's internal criteria to objective clinical evidence.

Don't stop after the first "no." The appeals process exists because denials are often wrong. Persistence isn't just an emotional decision, it's a strategic one.

An Easier Path: Let Claimable Handle Your Ubrelvy Appeal

If the process above feels like a lot, or if you've already been through one round of denials and don't have the energy for another, Claimable can take it from here.

Here's how it works:

Answer a few questions about your Ubrelvy denial and medical history. We build your case using our database of 4+ million clinical studies, insurer policies, and legal standards. We create a fully customized appeal with your personal story, clinical evidence, and policy analysis. We submit it for you — faxed and mailed directly to your insurer. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most resolved in 10 days or less.

"When my insurance company denied my claim to continue with my medicine, I felt defeated at first… Then I found Claimable. In the end I ended up winning my claim and I couldn't have done it without Claimable. I highly recommend them." – April A.

Appealing with Claimable costs $39.95. No success fees, no hidden costs – just a flat fee. If your migraine medication runs $1,000+ per month without coverage, the math speaks for itself.

Start your Ubrelvy appeal →

Appeal Timelines: How Long Does an Ubrelvy Appeal Take?

Submitting a complete, well-documented appeal from the start is the single best way to speed up the process. Incomplete submissions get delayed by requests for additional information. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Ubrelvy denied if my doctor prescribed it?

A prescription and an insurance approval are two different things. Most plans require prior authorization for Ubrelvy, and those PA criteria often include step therapy requirements (trying triptans first), quantity limits, and documentation thresholds that go beyond what your doctor submits with a standard prescription. Your doctor determined Ubrelvy is right for you medically – the insurer is applying a separate, often more restrictive, set of criteria.

What if I can't take triptans — do I still have to try them before getting Ubrelvy?

No – and this is one of the strongest appeal arguments for Ubrelvy. If you have cardiovascular conditions that contraindicate triptans, or documented intolerance or side effects from prior triptan use, those count as "failure" under most step therapy policies. Your appeal should include specific documentation of why triptans are inappropriate for you. The insurer cannot require you to take a medication that your doctor has determined is medically unsafe.

Can I appeal an Ubrelvy denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals carry their own legal protections – mandated response timelines, the right to escalate to external review, and multiple appeal levels. Your appeal is separate from anything your doctor's office files and doesn't depend on your doctor's appeal being successful.

Can I take Ubrelvy with an injectable CGRP medication like Aimovig or Emgality?

Published clinical evidence supports using Ubrelvy for acute treatment alongside a CGRP monoclonal antibody for prevention. They target different aspects of the CGRP pathway and serve different clinical purposes. If your insurer denied Ubrelvy based on "duplicate CGRP therapy," a clinical rationale from your neurologist citing the published safety data is typically the path to overturning it.

What's the difference between the 50mg and 100mg dose?

Both strengths are FDA-approved and showed similar pain freedom rates in clinical trials (21% at 2 hours for both 50mg and 100mg vs. 13% for placebo). For freedom from the most bothersome migraine symptoms – which includes nausea, sensitivity to light, and sensitivity to sound – rates were 38% for the 100mg tablet vs. 28% for placebo. The 100mg strength was also used in the PRODROME trial studying treatment during the early warning signs of a migraine and is often prescribed for patients with more severe attacks. Dose adjustments may also be needed based on other medications you take or kidney/liver function. If your insurer approved only the 50mg, your prescriber can submit a clinical rationale for the higher strength.

How many tablets of Ubrelvy should I be prescribed?

Ubrelvy's prescribing information establishes safety for treating up to 8 migraines per 30-day period, with the option for a second dose per attack. That means patients may need anywhere from 8 to 16 tablets per month depending on migraine frequency and whether a second dose is typically required. Insurer quantity limits vary: Some cap at 8 tablets, others at 10 or 16. If your prescribed quantity was denied, a quantity override request with clinical justification from your prescriber is the standard next step.

Is Ubrelvy the same as Nurtec?

No. Both are oral calcitonin gene-related peptide medications used in the treatment of migraines, but they're different drugs with different approvals. Ubrelvy (ubrogepant) is approved only for acute treatment, stopping a migraine attack in progress. Nurtec ODT (rimegepant) is approved for both acute treatment and prevention of episodic migraine. They also have different drug interaction profiles and dosing schedules. Other CGRP medications in the migraine landscape include Qulipta (atogepant), which is approved only for prevention, and Zavzpret (zavegepant), a nasal spray approved only for acute treatment. If your insurer wants you to switch to a different CGRP medication, your appeal should explain why Ubrelvy is the more appropriate choice for your specific situation.

How much does Ubrelvy cost without insurance?

The manufacturer's list price is approximately $1,085 for a month's supply. Retail prices can run higher, averaging around $1,300 for 10 tablets at some pharmacies. AbbVie offers the UBRELVY Complete Savings Card for commercially insured patients, which can reduce costs to as little as $0 per monthly fill (up to $7,000 in annual savings). Patients without commercial insurance who meet income requirements may qualify for AbbVie's patient assistance program (myAbbVie Assist), which provides the medication at no cost.

Is it worth appealing an Ubrelvy denial?

Absolutely. Insurers count on patients accepting a denial as final – fewer than 1% of denied claims are ever challenged. But appeals exist because denials are frequently wrong: documentation was incomplete, criteria were misapplied, or the insurer ignored clinical evidence. Your doctor prescribed Ubrelvy because you need it. The appeal is your opportunity to prove that case with the right evidence, the right arguments, and the right legal framework behind you.

Claimable's physician-led team has helped patients recover millions in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Related: Why Was My Migraine Treatment Denied? Common Insurance Denial Reasons and How to Fight Back